

SEP 28 2006
PATENT & TRADEMARK OFFICE

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

Complete if Known

Application Number	10/535,635
Filing Date	11/25/2003
First Named Inventor	Uyen K. Tran
Group Art Unit	1644
Examiner Name	Unassigned
Attorney Docket Number	071949-9701

Sheet	1	of	14
-------	---	----	----

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	T ⁶
--------------------	-----------------------	-------------------------	--	---------------------------------------	---------------------------------------	----------------

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/535,635
				Filing Date	11/25/2003
				First Named Inventor	Uyen K. Tran
				Group Art Unit	1644
				Examiner Name	Unassigned
				Attorney Docket Number	071949-9701
Sheet	2	of	14		

	Office ³	Number ⁴	Kind Code ⁵ (if known)				
B1		WO84/03564		COMMW SERUM LAB COMMISSION (AU)	1984-09-13		
B2		WO95/25116		CALIFORNIA INST OF TECHN (US)	1995-09-21		
B3		WO95/35505		UNIV LELAND STANFORD JUNIOR (US)	1995-12-28		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	Adam, M.A. et al, "Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions," (1988) <i>J. Virol.</i> 62:3802-3806	
	C2	Adams et al., "Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation," (1997) <i>J Clin Invest</i> 100:3149-3153	
	C3	Altschul, S.F. et al., "Basic local alignment search tool," (1990) <i>J. Mol. Biol.</i> 215:403-410	
	C4	Anderson, N.L. et al., "A comparison of selected mRNA and protein abundances in human liver," (1997) <i>Electrophoresis</i> 18:533-537	
	C5	Antinozzi, P.A. et al., "Metabolic engineering with recombinant adenoviruses," (1999) <i>Annu. Rev. Nutr.</i> 19:511-544	
	C6	Armentano, D. et al., "Effect of internal viral sequences on the utility of retroviral vectors," (1987) <i>J. Virol.</i> 61:1647-1650	
	C7	Arndt, G.M. et al., "A rapid genetic screening system for identifying gene-specific suppression constructs for use in human cells," (2000) <i>Nucleic Acids Res.</i> 28:E15	
	C8	Auwerx, J., "PPAR γ , the ultimate thrifty gene," (1999) <i>Diabetologia</i> 42:1033-1049	
	C9	Baltimore, D., "Intracellular immunization," (1988) <i>Nature</i> 335:395-396	
	C10	Barroso et al., "Dominant negative mutations in human PPAR associated with severe insulin resistance, diabetes mellitus and hypertension," (1998) <i>Nature</i> 402:880-883	
	C11	Bauer, G. et al., "Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized D34+cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes," (1997) <i>Blood</i> 89:2259-2267	

Examiner Signature	Date Considered	
-------------------------------	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/535,635 11/25/2003 Uyen K. Tran 1644 Unassigned 071949-9701
Sheet	3	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C12	Bender, M.A. et al., "Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region," (1987) <i>J. Virol.</i> 61:1639-1646	
	C13	Bitter, G.A. et al. (1987) <i>Methods Enzymol.</i> 153:516-544	
	C14	Black, R.A. et al., "A metalloproteinase disintegrin that releases tumour-necrosis factor- from cells," (1997) <i>Nature</i> 385:729-733	
	C15	Blaese, R.M. et al., "T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years," (1995) <i>Science</i> 270:475-480	
	C16	Blind, M. et al., "Cytoplasmic RNA modulators of an inside-out signal-transduction cascade," (1999) <i>Proc. Natl. Acad. Sci. USA</i> 96:3606-3610	
	C17	Boado, R.J. et al., "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS," (1998) <i>J. Pharm. Sci.</i> 87:1308-1315	
	C18	Bolton, A.E. et al., "The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent," (1973) <i>Biochem. J.</i> 133:529-539	
	C19	Bonyhadi, M.L., "RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication," (1997) <i>J. Virol.</i> 71:4707-4716	
	C20	Bordignon, C. et al., "Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients," (1995) <i>Science</i> 270:470-475	
	C21	Boulay, J.-L. et al., "Expression vectors and delivery systems," (1998) <i>Curr. Opin. Biotechnol.</i> 9:445-450	
	C22	Brody, E.N. et al., "Aptamers as therapeutic and diagnosis agents," (2000) <i>J. Biotechnol.</i> 74:5-13	
	C23	Broglie, R. et al., "Light-regulated expression of a pea Ribulose-1,5-Bisphosphate Carboxylase small subunit gene in transformed plant cells," (1984) <i>Science</i> 224:838-843	
	C24	Brummelkamp, T.R. et al., "A system for stable expression of short interfering RNAs in mammalian cells," (2002) <i>Science</i> 296:550-553	
	C25	Buller, R.M. et al., "Decreased virulence of recombinant Vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype," (1985) <i>Nature</i> 317:813-815	
	C26	Burge, C. et al, "Finding the genes in genomic DNA," (1997) <i>J. Mol. Biol.</i> 268:78-94	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Application Number	10/535,635
		Filing Date	11/25/2003
		First Named Inventor	Uyen K. Tran
		Group Art Unit	1644
		Examiner Name	Unassigned
Sheet 4 of 14	Attorney Docket Number	071949-9701	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C27	Burge, C. et al., "Prediction of complete gene structures in human genomic DNA," (1998) <i>Curr. Opin. Struct. Biol.</i> 8:346-354	
	C28	Burton, D.R., "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," (1991) <i>Proc. Natl. Acad. Sci. USA</i> 88:10134-10137	
	C29	Capecchi, M.R., "Altering the genome by homologous recombination," (1989) <i>Science</i> 244:1288-1292	
	C30	Caruthers, M.H. et al., "New chemical methods for synthesis in polynucleotides," (1980) <i>Nucleic Acids Symp. Ser.</i> 7:215-223	
	C31	Cavazzana-Calvo, M. et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," (2000) <i>Science</i> 288:669-672	
	C32	Chang, C.-C. et al., "Evolution of a cytokine using DNA family shuffling," (1999) <i>Nat. Biotechnol.</i> 17:793-797	
	C33	Chen, L. et al., "Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization," (1990) <i>Oncogene</i> 5:1391-1395	
	C34	Chicz, R.M. et al., "High-performance liquid chromatography: effective protein purification by various chromatographic modes," (1990) <i>Methods Enzymol.</i> 182:392-421	
	C35	Christians, F.C. et al., "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling," (1999) <i>Nat. Biotechnol.</i> 17:259-264	
	C36	Chung, T.D., "Characterization of the role of IL-6 in the progression of prostate cancer," (1999) <i>Prostate</i> 15:199-207	
	C37	Clarke, M.L. et al., "Comparative analysis of artificial antisense RNA regulation in fission yeast and human cells," (2000) <i>Biochem. Biophys. Res. Commun.</i> 268:8-13	
	C38	Colbere-Garapin, F. et al., "A new dominant hybrid selective marker for higher eukaryotic cells," (1981) <i>J. Mol. Biol.</i> 150:1-14	
	C39	Cole, S.P. et al., "Human monoclonal antibodies," (1984) <i>Mol. Cell Biol.</i> 62:109-120	
	C40	Coruzzi, G. et al., "Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of rebose-1,5-bisphosphate carboxylase," (1984) <i>EMBO J.</i> 3:1671-1680	
	C41	Cote, R.J. et al., "Generation of human monoclonal antibodies reactive with cellular antigens," (1983) <i>Proc. Natl. Acad. Sci. USA</i> 80:2026-2030	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Application Number	10/535,635
		Filing Date	11/25/2003
		First Named Inventor	Uyen K. Tran
		Group Art Unit	1644
		Examiner Name	Unassigned
Sheet	5	of	14
		Attorney Docket Number	071949-9701

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C42	Cramer, A. et al., "Improved green fluorescent protein by molecular evolution using DNA shuffling," (1996) <i>Nat. Biotechnol.</i> 14:315-319	
	C43	Crystal, R.G. et al., "A Phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung," (1995) <i>Hum. Gene Therapy</i> 6:643-666	
	C44	Crystal, R.G. et al., "Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis," (1995) <i>Hum. Gene Therapy</i> 6:667-703	
	C45	Crystal, R.G., "Transfer of genes to humans: Early lessons and obstacles to success," (1995) <i>Science</i> 270:404-410	
	C46	Csete, M.E. et al., "Efficient gene transfer to pancreatic islets mediated by adenoviral vectors," (1995) <i>Transplantation</i> 27:263-268	
	C47	Cunningham, B.C. et al., "Rational design of receptor-specific variants of human growth hormone," (1991) <i>Proc. Natl. Acad. Sci. USA</i> 88:3407-3411	
	C48	de la Fuente, M.A. et al., "CD84 leukocyte antigen is a new member of the Ig superfamily," (1997) <i>Blood</i> 90:2398-2405	
	C49	Davis, "The Many Faces of Epidermal Growth Factor Repeats," <i>The New Biologist</i> , Vol. 2, No. 5 (May), 1990, pp. 410-419	
	C50	Dryga, S.A. et al., "Identification of mutations in a sindbis virus variant able to establish persistent infection in BHK cells: The importance of a mutation in the nsP2 gene," (1997) <i>Virology</i> 228:74-83	
	C51	Dull, T. et al., "A third-generation lentivirus vector with a conditional packaging system," (1998) <i>J. Virol.</i> 72:8463-8471	
	C52	Duplaa, C. et al., "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) <i>Anal. Biochem.</i> 212:229-236	
	C53	Eddy, S.R., "Hidden markov models," (1996) <i>Curr. Opin. Struct. Biol.</i> 6:361-365	
	C54	Elbashir, S.M. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," (2001) <i>Nature</i> 411:494-498	
	C55	Engelhard, E.K. et al., "The insect tracheal system: a conduit for the systemic spread of Autographa californica M nuclear polyhedrosis virus," (1994) <i>Proc. Natl. Acad. Sci. USA</i> 91:3224-3227	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)				Application Number	10/535,635
				Filing Date	11/25/2003
				First Named Inventor	Uyen K. Tran
				Group Art Unit	1644
				Examiner Name	Unassigned
Sheet	6	of	14	Attorney Docket Number	071949-9701

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C56	Fields, S. et al., "A novel genetic system to detect protein-protein interactions," (1989) <i>Nature</i> 340:245-246	
	C57	Fire, A. et al., "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ," (1998) <i>Nature</i> 391:806-811	
	C58	Garoff, H. et al., Recent advances in gene expression using alphavirus vectors," (1998) <i>Curr. Opin. Biotechnol.</i> 9:464-469	
	C59	Gatti, R.A. et al., "Localization of an ataxia-telangiectasia gene to chromosome," (1988) <i>Nature</i> 336:577-580	
	C60	Gebe, J.A., "Molecular cloning, mapping to human chromosome 1q21-q23, and cell binding characteristics of Spq, a new member of the scavenger receptor cysteine-rich (SRCR) family of proteins," (1997) <i>J. Biol. Chem.</i> 272:6151-6158	
	C61	Goins, W.F. et al., "Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity," (1999) <i>J. Virol.</i> 73:519-532	
	C62	Gold, L.I., "The role for transforming growth factor- β (TGF- β) in human cancer," (1999) <i>Crit. Rev. Oncog.</i> 10:303-360	
	C63	Goldman, C.K. et al., "In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer," (1997) <i>Nat. Biotechnol.</i> 15:462-466	
	C64	Gossen, M. et al., "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters," (1992) <i>Proc. Natl. Acad. Sci. USA</i> 89:5547-5551	
	C65	Gossen, M. et al., "Transcriptional activation by tetracyclines in mammalian cells," (1995) <i>Science</i> 268:1766-1769	
	C66	Graham, F.L. et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA," (1973) <i>Virology</i> 52:456-467	
	C67	Gregoire et al., "Understanding adipocyte differentiation," (1998) <i>Physiol. Reviews</i> 78:783-809	
	C68	Gura, T., "A silence that speaks volumes," (2000) <i>Nature</i> 404:804-808	
	C69	Haft, D.H. et al., "TIGRFAMs: a protein family resource for the functional identification of proteins," (2001) <i>Nucleic Acids Res.</i> 29:41-43	
	C70	Harrington, J.J. et al., "Formation of de novo centromere and construction of first-generation human artificial microchromosomes," (1997) <i>Nat. Genet.</i> 15:345-355	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/535,635 11/25/2003 Uyen K. Tran 1644 Unassigned 071949-9701
Sheet	7	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C71	Harrington, M.G., "Elution of protein from gels," (1990) <i>Methods Enzymol.</i> 182:488-495	
	C72	Hartman, S.C. et al., "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," (1988) <i>Proc. Natl. Acad. Sci. USA</i> 85:8047-8051	
	C73	Heller, R.A. et al., "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays," (1997) <i>Proc. Natl. Acad. Sci. USA</i> 94:2150-2155	
	C74	Higgins, D.G. et al., "CLUSTAL V: Improved software for multiple sequence alignment," (1992) <i>CABIOS</i> 8:189-191	
	C75	Higgins, D.G. et al., "Fast and sensitive multiple sequence alignments on a microcomputer," (1989) <i>CABIOS</i> 5:151-153	
	C76	Horn, T. et al., "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for Gastric Inhibitory Polypeptide (GIP)," (1980) <i>Nucleic Acids Symp. Ser.</i> 7:225-232	
	C77	Hotasmisligil, "The role of TNF α and TNF receptors in obesity and insulin resistance," (1999) <i>J Intern Med</i> 245:621-625	
	C78	Howard, A.D. et al., "Orphan G-protein-coupled receptors and natural ligand discovery," (2001) <i>Trends Pharmacol. Sci.</i> 22:132-140	
	C79	Huse, W.D. et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in Phage Lambda," (1989) <i>Science</i> 246:1275-1281	
	C80	Ivics, Z., "Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells," (1997) <i>Cell</i> 91:501-510	
	C81	Khazaie, K. et al., "EGF receptor in neoplasia and metastasis," (1993) <i>Cancer and Metastasis Rev.</i> 12:255-274	
	C82	Kimmel, A.R., "Identification and characterization of specific clones: Strategy for confirming the validity of presumptive clones," (1987) <i>Methods Enzymol.</i> 152:507-511	
	C83	Kohler, G. et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," (1975) <i>Nature</i> 256:495-497	
	C84	Kozbor, D. et al., "Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas," (1985) <i>J. Immunol. Methods</i> 81:31-42	
	C85	Kwok, P.-Y. et al., "Single nucleotide polymorphism libraries: why and how are we building them?," (1999) <i>Mol. Med. Today</i> 5:538-543	

Examiner SigNature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Application Number	10/535,635
		Filing Date	11/25/2003
		First Named Inventor	Uyen K. Tran
		Group Art Unit	1644
		Examiner Name	Unassigned
Sheet 8 of 14	Attorney Docket Number	071949-9701	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C86	Lagerstrom, M. et al., "Capture PCR: efficient amplification of DNA fragments adjacent to a known sequence in human and YAC DNA," (1991) <i>PCR Methods Applic.</i> 1:111-119	
	C87	Lander, E.S. et al., "Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms," (1986) <i>Proc. Natl. Acad. Sci. USA</i> 83:7353-7357	
	C88	Lee, S.W. et al., "Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment," (1992) <i>Proc. Natl. Acad. Sci. USA</i> 89:2504-2508	
	C89	Letunic, I. et al., "Recent improvements to the SMART domain-based sequence annotation resource," (2002) <i>Nucleic Acids Res.</i> 30:242-244	
	C90	Lin, J. et al., "The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells," (1999) <i>Cancer Res.</i> 59:2891-2897	
	C91	Liu, X. et al., "Herpes simplex virus mediated gene transfer to primate ocular tissues," (1999) <i>Exp. Eye Res.</i> 169:385-395	
	C92	Logan, J. et al., "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection," (1984) <i>Proc. Natl. Acad. Sci. USA</i> 81:3655-3659	
	C93	Lois, C. et al., "Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors," (2002) <i>Science</i> 295:868-872	
	C94	Lowman, H.B. et al., "Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen," (1991) <i>J. Biol. Chem.</i> 266:10982-10988	
	C95	Lowy, I. et al., "Isolation of transforming DNA: cloning the hamster apt gene," (1980) <i>Cell</i> 22:817-823	
	C96	Lueking, A. et al., "Protein microarrays for gene expression and antibody screening," (1999) <i>Anal. Biochem.</i> 270:103-111	
	C97	Mantovani, A. et al., "Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines," (2001) <i>Trends Immunol.</i> 22:328-336	
	C98	Marshall, A. et al., "DNA Chips: an array of possibilities," (1998) <i>Nat. Biotechnol.</i> 16:27-31	
	C99	Marth, J.D., "Recent advances in gene mutagenesis by site-directed recombination," (1996) <i>Clin. Invest.</i> 97:1999-2002	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Complete if Known	
		Application Number	10/535,635
		Filing Date	11/25/2003
		First Named Inventor	Uyen K. Tran
		Group Art Unit	1644
		Examiner Name	Unassigned
		Attorney Docket Number	071949-9701
Sheet	9	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C100	Matthews, D.J. et al., "Engineering an interfacial zinc site to increase hormone-receptor affinity," (1994) <i>Chem. Biol.</i> 1:25-30	
	C101	McGregor, D.P. et al., "Spontaneous assembly of bivalent single chain antibody fragments in <i>Escherichia Coli</i> ," (1994) <i>Mol. Immunol.</i> 31:219-226	
	C102	McKenzie et al., "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function," (1993) <i>Proc Natl Acad Sci</i> 90:3735-3739	
	C103	Melby, P.C. et al., "Quantitative measurement of human cytokine gene expression by polymerase chain reaction," (1993) <i>J. Immunol. Methods</i> 159:235-244	
	C104	Mendoze, L.G. et al., "High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA)," (1999) <i>Biotechniques</i> 27:778-788	
	C105	Miller, A.D., "Progress toward human gene therapy," (1990) <i>Blood</i> 76:271-278	
	C106	Mitra, R.D. et al., "Fluorescence resonance energy transfer between blue-emitting and red-shifting excitation derivatives of the green fluorescent protein," (1996) <i>Gene</i> 173:13-17	
	C107	Morgan, R.A. et al., "Human gene therapy," (1993) <i>Annu. Rev. Biochem.</i> 62:191-217	
	C108	Morris, M.C. et al., "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," (1997) <i>Nucleic Acids Res.</i> 25:2730-2736	
	C109	Morrison, S.L. et al. (1984) <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855	
	C110	Murphy et al., "Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells," (2000) <i>J Biol Chem</i> 274:5830-5834	
	C111	Muyldermans, S., "Single domain camel antibodies: current status," (2001) <i>J. Biotechnol.</i> 74:277-302	
	C112	Neuberger, M.S. et al., "Recombinant antibodies possessing novel effector functions," (1984) <i>Nature</i> 312:604-608	
	C113	Neumann, E. et al., "Gene transfer into mouse lyoma cells by electroporation in high electric fields," (1982) <i>EMBO J.</i> 1:841-845	
	C114	Nowotny, P. et al., "SNP analysis to dissect human traits," (2001) <i>Curr. Opin. Neurobiol.</i> 11:637-641	

Examiner SigNature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Application Number	10/535,635
		Filing Date	11/25/2003
		First Named Inventor	Uyen K. Tran
		Group Art Unit	1644
		Examiner Name	Unassigned
Sheet 10 of 14	Attorney Docket Number	071949-9701	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C115	Nuwaysir, E.F. et al., "Microarrays and toxicology: the advent of toxicogenomics," (1999) <i>Mol. Carcinog.</i> 24:153-159	
	C116	Oba, K. et al., "Two putative tumor suppressor genes on chromosome 8p may play different roles in prostate cancer," (2001) <i>Cancer Genet. Cytogenet.</i> 124: 20-26	
	C117	Orlandi, R. et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) <i>Proc. Natl. Acad. Sci. USA</i> 86:3833-3837	
	C118	Paddison, P.J. et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," (2002) <i>Genes Dev.</i> 16:948-958	
	C119	Parker, J.D. et al., "Targeted gene walking polymerase chain reaction," (1991) <i>Nucleic Acids Res.</i> 19:3055-3060	
	C120	Perou, C.M. et al., "Molecular portraits of human breast tumours," (2000) <i>Nature</i> 406:747-752	
	C121	Pickup and Crook, "Is Type II diabetes mellitus a disease of the innate immune system?," (1998) <i>Diabetologia</i> 41:1241-8	
	C122	Poeschla, E. et al., "Development of HIV vectors for anti-HIV gene therapy," (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93:11395-11399	
	C123	Punnonen et al., "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells," (1993) <i>Proc Natl Acad Sci</i> 90:3730-3734	
	C124	Putz, T. et al., "Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines," (1999) <i>Cancer Res.</i> 59:227-233	
	C125	Ranga, U. et al., "Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene," (1997) <i>J. Virol.</i> 71:7020-7029	
	C126	Ranga, U. et al., "Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals," (1998) <i>Proc. Natl. Acad. Sci. USA</i> 95:1201-1206	
	C127	Rao, V.B., "Direct sequencing of polymerase chain reaction-amplified DNA," (1994) <i>Anal. Biochem.</i> 216:1-14	
	C128	Raper, "Semaphorins and Their Receptors in Vertebrates and Invertebrates," 2000, pp. 88-94	
	C129	Rhodes, C.A., "Transformation of maize by electroporation of embryos," (1995) <i>Methods Mol. Biol.</i> 55:121-131	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Application Number	10/535,635
		Filing Date	11/25/2003
		First Named Inventor	Uyen K. Tran
		Group Art Unit	1644
		Examiner Name	Unassigned
Sheet 11 of 14	Attorney Docket Number	071949-9701	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C130	Riviere, I. et al., "Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells," (1995) <i>Proc. Natl. Acad. Sci. USA</i> 92:6733-6737	
	C131	Roberge, J.Y. et al., "A strategy for a convergent synthesis of N-linked glycopeptides on a solid support," (1995) <i>Science</i> 269:202-204	
	C132	Rossi, F.M.V. et al., "Recent advances in inducible gene expression systems," (1998) <i>Curr. Opin. Biotechnol.</i> 9:451-456	
	C133	Rossi, J.J., "Therapeutic antisense and ribozymes," (1995) <i>Br. Med. Bull.</i> 51:217-225	
	C134	Sager, R. et al., "Maspin: A tumor suppressing serpin," (1996) <i>Curr. Top. Microbiol. Immunol.</i> 213:51-64	
	C135	Sagot, I. et al., "Imaging fluorescence resonance energy transfer between two green fluorescent proteins in living yeast," (1999) <i>FEBS Letters</i> 447:53-57	
	C136	Sandig, V. et al., "Gene transfer into hepatocytes and human liver tissue by baculovirus vectors," (1996) <i>Hum. Gene Ther.</i> 7:1937-1945	
	C137	Sarkar, G., "Restriction-site PCR: a direct method of unknown sequence retrieval adjacent to a known locus by using universal primers," (1993) <i>PCR Methods Applic.</i> 2:318-322	
	C138	Scanlon, K.J. et al., "Oligonucleotide-mediated modulation of mammalian gene expression," (1995) <i>FASEB J.</i> 9:1288-1296	
	C139	Scharf, D. et al., "Heat stress promoters and transcription factors," (1994) <i>Results Probl. Cell Differ.</i> 20:125-162	
	C140	Schena, M. et al., "Parallel human genome analysis: microarray-based expression monitoring of 1000 genes," (1996) <i>Proc. Natl. Acad. Sci. USA</i> 93:10614-10619	
	C141	Schena, M. et al., "Quantitative monitoring of gene expression patterns with a complementary DNA microarray," (1995) <i>Science</i> 270:467-470	
	C142	Schlöndorff, J. et al., "Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding," (1999) <i>J. Cell. Sci.</i> 112:3603-3617	
	C143	Schultz, J. et al., "SMART, a simple modular architecture research tool: Identification of signaling domains," (1998) <i>Proc. Natl. Acad. Sci. USA</i> 95:5857-5864	
	C144	Schwarze, S.R. et al., "In vivo protein transduction: delivery of a biologically active protein into the mouse," (1999) <i>Science</i> 285:1569-1572	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Application Number	10/535,635
		Filing Date	11/25/2003
		First Named Inventor	Uyen K. Tran
		Group Art Unit	1644
		Examiner Name	Unassigned
Sheet 12 of 14	Attorney Docket Number	071949-9701	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C145	Scorer, C.A. et al., "Rapid selection using G418 of high copy number transformants of <i>Pichia Pastoris</i> for high-level foreign gene expression," (1994) <i>Bio/Technology</i> 12:181-184	
	C146	Sears, D.W. et al., "Molecular Cloning and Expression of the Mouse High Affinity Fc Receptor for IgG," (1990) <i>J. Immunol.</i> 144:371-378	
	C147	Shalon, D. et al., "A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization," (1996) <i>Genome Res.</i> 6:639-645	
	C148	Sharma et al., "TGF-beta in diabetic kidney disease: role of novel signaling pathways," (2000) <i>Cytokine Growth Factor Rev</i> 11:115-123	
	C149	Skerra, A., "Anticalins: A new class of engineered ligand-binding proteins with antibody-like properties," (2001) <i>J. Biotechnol.</i> 74:257-275	
	C150	Skolnik et al., "Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus," (1996) <i>Cytokine Growth Factor Rev</i> 7:161-173	
	C151	Slater, J.E. et al., "Environmental and occupational disorders," (1998) <i>J. Allergy Clin. Immunol.</i> 102:469-475	
	C152	Smith, et al., "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Constimulation, and Death, <i>Cell</i> , Vol. 76, Mar. 1994, pp. 959-962	
	C153	Steiner, S. et al., "Expression profiling in toxicology—potentials and limitations," (2000) <i>Toxicol. Lett.</i> 112-113:467-471	
	C154	Su, L., "Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro," (1997) <i>Blood</i> 89:2283-2290	
	C155	Takamatsu, N., "Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TRV-RNA," (1987) <i>EMBO J.</i> 6:307-311	
	C156	Takeda, S. et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," (1985) <i>Nature</i> 314:452-454	
	C157	Taylor, "Using genetic variation to study human disease," (1999) <i>Cell</i> 97:9-12	
	C158	Taylor, J.G. et al., "Deconstructing type 2 diabetes," (2001) <i>Trends Mol. Med.</i> 7:507-512	
	C159	Taylor, P.C. et al., "Immunotherapy for rheumatoid arthritis," (2001) <i>Curr. Opin. Immunol.</i> 13:611-616	

Examiner SigNature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/535,635
		Filing Date	11/25/2003
		First Named Inventor	Uyen K. Tran
		Group Art Unit	1644
		Examiner Name	Unassigned
Date Submitted: September 28, 2006		Attorney Docket Number	071949-9701
(use as many sheets as necessary)			
Sheet	13	of	14

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C160	Thomson, J.A. et al., "Embryonic stem cell lines derived from human blastocysts," (1998) <i>Science</i> 282:1145-1147	
	C161	Trask, B.J., "Fluorescence in situ hybridization," (1991) <i>Trends Genet.</i> 7:149-154	
	C162	Triglia, T. et al., "A procedure for in vitro amplification of DNA segments that lie outside the boundaries of known sequences," (1988) <i>Nucleic Acids Res.</i> 16:8186	
	C163	Uckert, W. et al., "Retrovirus-mediated gene transfer in cancer therapy," (1994) <i>Pharmacol. Ther.</i> 63:323-347	
	C164	Ulrix, W. et al., "The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells," (1999) <i>FEBS Lett</i> 455:23-26	
	C165	Van Heeke, G. et al., "Expression of human synthetase in <i>Escherichia coli</i> ," (1989) <i>J. Biol. Chem.</i> 264:5503-5509	
	C166	Verma, I.M. et al., "Gene therapy - promises, problems and prospects," (1997) <i>Nature</i> 389:239-242	
	C167	Wagner, K.U. et al., "Cre-mediated gene deletion in the mammary gland," (1997) <i>Nucleic Acids Res.</i> 25:4323-4330	
	C168	Wahl, G.M. et al., "Molecular hybridization of immobilized nucleic acids: theoretical concepts and practical considerations," (1987) <i>Methods Enzymol.</i> 152:399-407	
	C169	Way et al., "Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues," (2001) <i>Endocrinology</i> 142:1269-1277	
	C170	Weiss, G.A. et al., "Anticalins versus antibodies: made-to-order binding proteins for small molecules," (2000) <i>Chem. Biol.</i> 7:R177-R184	
	C171	Wigler, M. et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," (1977) <i>Cell</i> 11:223-232	
	C172	Wigler, M. et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) <i>Proc. Natl. Acad. Sci. USA</i> 77:3567-3570	
	C173	Winter, G. et al., "Man-made antibodies," (1991) <i>Nature</i> 349:293-299	
	C174	Winter, J. et al., "The expression of heat shock protein and cognate genes during plant development," (1991) <i>Results Probl. Cell Differ.</i> 17:85-105	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 09/28/2006

10535635 - GAU: 1644

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 28, 2006 (use as many sheets as necessary)		Complete if Known <table border="1"> <tr> <td>Application Number</td> <td>10/535,635</td> </tr> <tr> <td>Filing Date</td> <td>11/25/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Uyen K. Tran</td> </tr> <tr> <td>Group Art Unit</td> <td>1644</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>071949-9701</td> </tr> </table>		Application Number	10/535,635	Filing Date	11/25/2003	First Named Inventor	Uyen K. Tran	Group Art Unit	1644	Examiner Name	Unassigned	Attorney Docket Number	071949-9701
Application Number	10/535,635														
Filing Date	11/25/2003														
First Named Inventor	Uyen K. Tran														
Group Art Unit	1644														
Examiner Name	Unassigned														
Attorney Docket Number	071949-9701														
Sheet	14	of	14												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C175	Wise, A. et al., "Target validation of G-protein coupled receptors," (2002) <i>Drug Discovery Today</i> 7:235-246	
	C176	Wistuba, I.I. et al., "Comparison of features of human breast cancer cell lines and their corresponding tumors," (1998) <i>Clin. Cancer Res.</i> 4:2931-2938	
	C177	Xu, H. et al., "Viral transduction of trkA into cultured nodose and spinal motor newrons conveys NGF responsiveness," (1994) <i>Dev. Biol.</i> 163:152-161	
	C178	Yamamoto, S. et al., "ADAM family proteins in the immune system," (1999) <i>Immunol. Today</i> 20:278-84	
	C179	Yu, M. et al., "A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus Type 1," (1993) <i>Proc. Natl. Acad. Sci. USA</i> 90:6340-6344	
	C180	Yu, X. et al., "Characterization of the Promoter of Human Leukocyte-Specific Transcript 1," (2000) <i>J. Biol. Chem.</i> 275:34597-34608	
	C181	Zabner, J. et al., "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in masal epithelia of patients with cystic fibrosis," (1993) <i>Cell</i> 75:207-216	
	C182	Zhou, Z. et al., "Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors," (1998) <i>Int. J. Cancer</i> 78:95-99	
	C183	Zufferey, R. et al., "Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery," (1998) <i>J. Virol.</i> 72:9873-9880	

Examiner SigNature	/Michael Szperka/	Date Considered	10/30/2008
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1694290.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MS/